Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp406 | Osteoporosis: treatment | ECTS2013

In real clinical practice osteoporosis drugs are taken for a very short period: analysis of persistence in the campania region

Iolascon Giovanni , Capaldo Annarita , Orlando Valentina , Menditto Enrica , Gimigliano Francesca

Introduction: Persistence is defined as the period between the start and the interruption of a pharmacological treatment. In osteoporotic patients, persistence to therapy is poor, resulting in reduced benefits and increased risk of fracture.The aim of this study is to analyze persistence with drug therapy in osteoporotic patients in the Campania region.Material and methods: We conducted a retrospective population-based cohort study to examine prescriptio...

ba0001pp419 | Osteoporosis: treatment | ECTS2013

Analysis of clinical assessment and efficacy of once-yearly i.v. zoledronic acid for osteoporosis

Park Ye-Soo , Kim Hong-Sik , Lee Jung-Hwan , Won Ye-Yeon , Kang Byung-Moon

Introduction: To analyze clinical assessment and efficacy of once-yearly i.v. zoledronic acid for osteoporosis.Materials and methods: The subjects were 322 osteoporotic patients who received more than single infusion of zoledronic acid in our hospital from October 2008 to March 2011. On clinical assessment, the adherence was evaluated by measuring the rate of reinfusion. Adverse events were recorded for safety assessment. For efficacy assessment, the bon...

ba0001pp423 | Osteoporosis: treatment | ECTS2013

Three years' experience of zoledronic acid use in the treatment of postmenopausal osteoporosis

Yureneva Svetlana , Yakushevskaya Oksana , Kuznetsov Sergey , Ivanets Tatyana , Smetnik Vera , Sukchich Gennady

Introduction: We aimed to study efficacy of zoledronic acid (Zol) in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, bone mineral density (BMD) by DEXA (L1–L4, femoral Neck) (baseline, 12, 24, and 36 months); biochemical; immunoenzyme assay of bone turnover markers (BTM) – osteocalcin (OK) β-C-terminal telopeptides of type 1 collagen (CTX) (baseline, 1, 3, 6, 9, and 12 after one, two, three infusions).<p ...

ba0001pp426 | Osteoporosis: treatment | ECTS2013

Characterization and incidence on acute phase reaction in Paget's disease after zoledronic acid infusion

Mateos A Conesa , Sala D Rotes , Abello J Carbonell

Zoledronic acid (AZ), is considered first-line treatment for Paget’s disease (PD) of bone. The most common adverse event is flu-like syndrome, described between 10 and 50% of patients. Nowadays, there is not known exactly the molecular basis of this syndrome yet. Statins play an important role in the mevalonate pathway, blocking the production of proinflammatory cytokines secreted by T cells γ/δ.Objectives: Characterization and in...

ba0001pp429 | Osteoporosis: treatment | ECTS2013

Study description and baseline characteristics of the population enrolled in the extended forsteo® observational study (ExFOS)

Langdahl Bente , Benhamou Claude , Lindh Erik , Dekker Joannes , Kapetanos Giorgios , Kocjan Tomaz , Ljunggren Osten , Napoli Nicola , Petto Helmut , Nicolic Tatjana

ExFOS is a multicenter, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in female and male patients with osteoporosis treated with teriparatide [rhPTH(1–34)] (Forsteo)for 18 to 24 months. Post-treatment follow-up will last for at least 18 months. Patients were enrolled in Croatia, Denmark, France, Greece, Italy, Norway, Slovenia, and Sweden. The study design was non-interventional and all consenting ...

ba0001pp443 | Osteoporosis: treatment | ECTS2013

Zoledronic acid vs alendronate in the management of osteoporosis

Ferguson Lyn , Panarelli Maurizio , Dargie Rosemary

Zoledronic acid has been shown to reduce the risk of fractures and improve bone mineral density (BMD) in osteoporosis vs placebo. This study compared changes in BMD in patients with osteoporosis treated with zoledronic acid vs alendronate. BMD at the lumbar spine and total hip pre- and post-bisphosphonate were recorded for 65 patients with osteoporosis (T score ≤−2.5) from retrospective analysis of DEXA scans. 35 patients received annual 5 mg IV zoledronic...

ba0001pp459 | Other diseases of bone and mineral metabolism | ECTS2013

Correlates of tissue mineral density of bone samples from total hip arthroplasty patients with type 2 diabetes: an ex vivo study

Pritchard Janet , Papaioannou Alexandra , Hurtig Mark , Giangregorio Lora , Atkinson Stephanie , Beattie Karen , Adachi J.D. , DeBeer Justin , Winemaker Mitchell , Avram Victoria , Schwarcz Henry

Introduction: Fracture risk is greater for adults with type 2 diabetes (T2D), despite normal or higher areal bone mineral density (aBMD) compared to controls. Tissue mineral density (TMD), measured by microCT, is more representative of actual mineral density than in vivo aBMD. The aim of this study was to determine whether TMD is greater in adults with T2D, and to investigate the correlates of TMD in adults with T2D.Methods: Using proximal femur...

ba0002is3 | The fracturing child: biology | ICCBH2013

Bone structure and fractures

Kirmani Salman

The incidence of distal forearm fractures in children is increasing, and peaks during the adolescent growth spurt. Advances in bone imaging have allowed us and other groups to obtain non-invasive ‘virtual bone biopsy’ data in growing children using high resolution peripheral quantitative computed tomography (HRpQCT). We studied changes in bone structure at the distal radius in individuals ranging from age 6 to till 21 years using HRpQCT. Transient regional deficits i...

ba0002p51 | (1) | ICCBH2013

Mild visual impairment in a 13-year-old child with osteoporosis-pseudoglioma syndrome

Cheung Moira , Brain Caroline , Allgrove Jeremy

Background: Osteoporosis-pseudoglioma (OPPG) syndrome is an autosomal recessive disorder characterised by severe juvenile osteoporosis and congenital or infancy-onset visual loss. OPPG is caused by loss of function mutations in LDL receptor-related protein 5 (LRP5) gene. We present a 13-year-old child with a homozygous mutation in LRP5 and low bone mass but without visual loss.Presenting problem/clinical management: This child presented with multiple low...

ba0002p89 | (1) | ICCBH2013

Painful vertebral fractures during pregnancy: be aware of a potentially underlying genetic cause

Zillikens M Carola , Campos-Obando Natalia , Oei Ling , Simon Marleen

Background: The baby growing in its mother’s womb needs calcium for skeletal development. Maternal osteoporosis has been attributed to pregnancy in some cases.Presenting problem: A 27-year-old woman in the 7th month of her first pregnancy complained of mid-thoracic back pain after lifting a non-heavy object. The pain remained with differing intensity and was attributed to her pregnancy. After the delivery of a healthy child, the back pain prevented ...